^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    2d
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    2d
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    17d
    A Prospective, Multicenter, Single-arm Phase II Study Evaluating the Efficacy and Safety of Polatuzumab Vedotin in Combination with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZRCHP) in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (ChiCTR2600119915)
    P2, N=48, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    18d
    A single-arm, prospective, phase II study of Glofitamab in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin,and Prednisone (Pola-R-CHP) to optimize primary therapy in patients with high-risk Diffuse Large B-Cell Lymphoma assessed by interim FDG PET and ctDNA (ChiCTR2600118538)
    P2, N=42, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial • Circulating tumor DNA
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    19d
    Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. (PubMed, Blood)
    This is the first bispecific-ADC combination therapy study in MCL. (Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT03671018).
    P2 data • Journal
    |
    TP53 (Tumor protein P53) • CD79B (CD79b Molecule)
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    24d
    Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    24d
    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=5, Terminated, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Funding
    Trial completion date • Trial termination
    |
    cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    25d
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    1m
    R-Pola-Glo: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Sep 2028 --> Feb 2028
    Trial completion date
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1m
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1m
    TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Brown University
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule) • IRF4 (Interferon regulatory factor 4)
    |
    Gazyva (obinutuzumab) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1m
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)